A Phase 2 interventional study of ACT-128800 Dose 1 and Placebo in Multiple Sclerosis, sponsored by Actelion. Completed at 115 sites in 23 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 78th largest by enrollment of the 879 interventional ones that give a count, is one of 39 that started in 2009, is one of 139 in phase 2, and was the 216th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 40–70
University of Texas at Austin · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,192 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 191 · Phase 3 142 · Phase 4 82
First in 1976; this study’s year is marked. 39 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 464 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 50 across the 879 interventional studies, 100 across the 302 observational. Of the 818 that completed or were terminated, 332 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
376 of 1,192 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
Johnson & Johnson has 7 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
78 of the studies in Multiple Sclerosis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT06136728Phase 3MGH Institute of Health ProfessionsDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | 2027-05 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
Add all 78 to your calendar (.ics) → With an account.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ACT-128800 Dose 1
Drug: ACT-128800 Dose 1
ACT-128800 Dose 2
Drug: ACT-128800 Dose 2
ACT-128800 Dose 3
Drug: ACT-128800 Dose 3
Matching placebo
Drug: Placebo
ACT-128800 (Dose 1) administered orally once daily
Matching placebo administered orally once daily
ACT-128800 (Dose 2) administered orally once daily
ACT-128800 (Dose 3) administered orally once daily
Cumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 24
Cumulative Number of new T1 gadolinium-enhancing (Gd+) lesions per year on magnetic resonance imaging (MRI) scan from Week 12 to Week 24 were reported. Negative binomial (NB) regression analysis on Per protocol analysis set and imputation was applied for the missing data. Here, MS signifies multiple sclerosis.
Time frame: From Week 12 to 24
Annualized Confirmed Relapse Rate
Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple Sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicating overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS with information concerning gait and use of assistance. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10(death due to MS)
Time frame: Up to 24 weeks
Number of Participants With First Confirmed Relapse as Assessed by Kaplan-Meier Estimate From Baseline to Week 24
Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of MS, not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicating overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS with information concerning gait and use of assistance. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10(death due to MS). Kaplan-Meier estimate used for Outcome Measure analysis.
Time frame: Baseline to Week 24
| Milestone | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo |
|---|---|---|---|---|
| Started | 119 | 116 | 108 | 121 |
| Treated | 119 | 114 | 108 | 121 |
| Completed | 113 | 107 | 99 | 116 |
| Not completed | 6 | 9 | 9 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 7 | 5 | 5 |
| Withdrew: Administrative reason | 1 | 2 | 3 | 0 |
Cumulative Number of new T1 gadolinium-enhancing (Gd+) lesions per year on magnetic resonance imaging (MRI) scan from Week 12 to Week 24 were reported. Negative binomial (NB) regression analysis on Per protocol analysis set and imputation was applied for the missing data. Here, MS signifies multiple sclerosis.
| Lesions | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo |
|---|---|---|---|---|
| Cumulative Number of New T1 Gadolinium-Enhancing (Gd+) Lesions on Magnetic Resonance Imaging (MRI) Scan From Week 12 to Week 24 | 1.4 ± 3.24 | 1.1 ± 1.96 | 3.5 ± 7.27 | 6.2 ± 13.42 |
Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple Sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicating overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS with information concerning gait and use of assistance. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10(death due to MS)
| Relapse per year | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo |
|---|---|---|---|---|
| Annualized Confirmed Relapse Rate | 0.224 ± 0.7834 | 0.396 ± 1.0169 | 0.297 ± 0.7987 | 0.601 ± 1.6626 |
Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of MS, not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicating overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS with information concerning gait and use of assistance. EDSS is ordinal clinical scale ranges 0 (normal neurological examination) to 10(death due to MS). Kaplan-Meier estimate used for Outcome Measure analysis.
| Participants | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With First Confirmed Relapse as Assessed by Kaplan-Meier Estimate From Baseline to Week 24 | 10 | 17 | 14 | 25 |
Collected over Up to 29 weeks (AEs for Treatment duration (24 weeks) and follow up (5 Weeks) on Day 7 and Day 30 after last dose). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ponesimod 40 mg | 0/119 (0%) | 3/119 (2.5%) | 83/119 (69.7%) |
| Ponesimod 20 mg | 0/114 (0%) | 7/114 (6.1%) | 73/114 (64%) |
| Ponesimod 10 mg | 0/108 (0%) | 7/108 (6.5%) | 69/108 (63.9%) |
| Placebo | 0/121 (0%) | 5/121 (4.1%) | 77/121 (63.6%) |
| Event | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo |
|---|---|---|---|---|
| Atrioventricular Block Second DegreeCardiac disorders | 0/119 | 1/114 | 2/108 | 0/121 |
| Macular OedemaEye disorders | 0/119 | 2/114 | 0/108 | 0/121 |
| Coronary Artery DiseaseCardiac disorders | 0/119 | 0/114 | 1/108 | 0/121 |
| VertigoEar and labyrinth disorders | 0/119 | 0/114 | 1/108 | 0/121 |
| PyrexiaGeneral disorders | 0/119 | 0/114 | 1/108 | 0/121 |
| Alanine Aminotransferase IncreasedInvestigations | 0/119 | 0/114 | 1/108 | 0/121 |
| Aspartate Aminotransferase IncreasedInvestigations | 0/119 | 0/114 | 1/108 | 0/121 |
| Electrocardiogram QT ProlongedInvestigations | 0/119 | 0/114 | 1/108 | 0/121 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/119 | 0/114 | 1/108 | 0/121 |
| SomnolenceNervous system disorders | 0/119 | 0/114 | 1/108 | 0/121 |
| Event | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 15/119 | 16/114 | 15/108 | 18/121 |
| NasopharyngitisInfections and infestations | 13/119 | 12/114 | 16/108 | 17/121 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 16/119 | 7/114 | 5/108 | 4/121 |
| Oedema PeripheralGeneral disorders | 13/119 | 3/114 | 2/108 | 2/121 |
| Disease ProgressionGeneral disorders | 11/119 | 9/114 | 10/108 | 6/121 |
| Upper Respiratory Tract InfectionInfections and infestations | 11/119 | 9/114 | 4/108 | 11/121 |
| DizzinessNervous system disorders | 11/119 | 7/114 | 8/108 | 3/121 |
| FatigueGeneral disorders | 6/119 | 9/114 | 7/108 | 7/121 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/119 | 3/114 | 1/108 | 2/121 |
| DiarrhoeaGastrointestinal disorders | 3/119 | 3/114 | 3/108 | 8/121 |
All-randomized analysis set included all randomized participants, whether or not they received study drug.
| Age, Continuous(years) | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Age ( years ) | 36.5 ± 8.52 | 35.3 ± 8.52 | 36.9 ± 9.24 | 36.6 ± 8.58 | 36.3 ± 8.7 |
| Sex: Female, Male(Participants) | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Gender — Female | 79 | 78 | 71 | 85 | 313 |
| Gender — Male | 40 | 38 | 37 | 36 | 151 |
| Ethnicity (NIH/OMB)(Participants) | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 117 | 116 | 108 | 121 | 462 |
| Race (NIH/OMB)(Participants) | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 1 | 0 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 2 | 6 | 12 |
| White | 114 | 114 | 105 | 114 | 447 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 2 |
| Region of Enrollment(Participants) | Ponesimod 40 mg | Ponesimod 20 mg | Ponesimod 10 mg | Placebo | Total |
|---|---|---|---|---|---|
| Australia | 0 | 1 | 0 | 0 | 1 |
| Austria | 2 | 2 | 2 | 3 | 9 |
| Belgium | 2 | 0 | 0 | 0 | 2 |
| Bulgaria | 5 | 4 | 5 | 5 | 19 |
| Canada | 3 | 3 | 4 | 3 | 13 |
| Finland | 6 | 4 | 4 | 6 | 20 |
| Czech Republic | 14 | 14 | 12 | 12 | 52 |
| France | 1 | 1 | 1 | 1 | 4 |
| Germany | 1 | 2 | 1 | 2 | 6 |
| Hungary | 7 | 7 | 2 | 3 | 19 |
| Israel | 3 | 2 | 1 | 3 | 9 |
| Italy | 8 | 7 | 6 | 7 | 28 |
| Netherlands | 1 | 1 | 2 | 2 | 6 |
| Poland | 7 | 8 | 10 | 12 | 37 |
| Romania | 1 | 2 | 3 | 3 | 9 |
| Russia | 9 | 9 | 8 | 7 | 33 |
| Spain | 4 | 2 | 3 | 4 | 13 |
| Serbia | 10 | 10 | 11 | 11 | 42 |
| Sweden | 5 | 6 | 4 | 6 | 21 |
| Switzerland | 0 | 2 | 2 | 1 | 5 |
| United Kingdom | 5 | 5 | 4 | 4 | 18 |
| Ukraine | 5 | 6 | 5 | 7 | 23 |
| United States | 20 | 18 | 18 | 19 | 75 |
Showing the first 100 of 115 sites across 23 countries. Choose a country and city above to see the rest.
Ran from Oct 2009 to primary completion in Jun 2011, 20 months.
Results were first posted in Jun 2021, 10 years after primary completion. A results delay was requested in Sep 2012.
Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 20 months is below that.
Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ponesimod